Retatrutide 30mg | NeuroPept Labs

Description

Retatrutide (LY3437943) is a synthetic 39-amino acid research peptide studied as a triple receptor agonist targeting the GLP-1 (glucagon-like peptide-1), GIP (gastric inhibitory polypeptide), and glucagon receptors simultaneously. This triple-action receptor profile distinguishes it from single-target GLP-1 agonists and dual-target compounds such as tirzepatide, making it one of the most studied metabolic research peptides in preclinical and clinical investigation.

NeuroPept Labs supplies Retatrutide 30mg as a research-grade lyophilized peptide intended strictly for in vitro laboratory and analytical research use. All batches are manufactured under controlled synthesis conditions and verified through third-party analytical testing. COA validity can be confirmed at freedomdiagnosticstesting.com using the Accession Number, Client ID, or Search Code found in the product images.

Mechanism of Action (Research Overview)

Retatrutide exhibits agonist activity at three distinct receptor pathways:

• GLP-1 Receptor (GLP-1R) “” stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, reduces gastric emptying, and modulates appetite signaling.
• GIP Receptor (GIPR) “” augments insulin secretion post-meal and supports lipid clearance, complementing GLP-1R signaling for enhanced glycemic modulation.
• Glucagon Receptor (GCGR) “” the key differentiator from dual agonists; glucagon receptor activation promotes hepatic fat metabolism, increases energy expenditure, and contributes to lipolysis and fatty acid oxidation.

This combination is referred to in the research literature as “Triple G” receptor agonism and has demonstrated up to 24.2% mean weight reduction in Phase 2 obesity trials over 48 weeks.

Research Significance

Retatrutide is currently in Phase 3 clinical trials and is considered one of the most promising investigational compounds in metabolic research. Key areas of research interest include:

• Metabolic dysfunction and obesity-associated pathways
• Type 2 diabetes glycemic regulation models
• Hepatic lipid metabolism and NAFLD/NASH research
• Cardiometabolic risk factor evaluation
• Receptor selectivity and tri-agonist pharmacology

Phase 2 data also demonstrated up to 82% reduction in liver fat in NASH-related research models.

Product Specifications

Storage and Handling

• Store lyophilized peptide at -20°C or below prior to reconstitution
• Avoid repeated freeze-thaw cycles to preserve structural integrity
• Protect from direct light, humidity, and room temperature exposure
• Reconstitute using appropriate sterile laboratory solvents under aseptic conditions
• Once reconstituted, store at 4°C and use within recommended research timeframes

Frequently Asked Questions

Scientific References

1. Triple-Hormone-Receptor Agonist Retatrutide for Obesity “” Phase 2 Trial, NEJM 2023
2. Efficacy and Safety of Retatrutide “” PMC / NIH 2025
3. Triple Agonism Based Therapies for Obesity “” PMC / NIH 2025
4. Triple Hormone Receptor Agonist Retatrutide for Metabolic Dysfunction “” PMC 2024
5. Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist “” ScienceDirect / The Lancet

Additional information